CNM-Au8 shows survival benefit after 3.5 years: Analysis
After up to 3.5 years on the experimental oral treatment CNM-Au8, the chances of survival for people with…
Articles by Marisa Wexler, MS
$2M grant supports new clinical trial of MyoRegulator for ALS
The U.S. Department of Defense (DoD) has awarded more than $2 million to help Pathmaker Neurosystems conduct a…
Qalsody approved in European Union to treat SOD1-ALS
The European Commission has approved Qalsody (tofersen) as a treatment for amyotrophic lateral sclerosis (ALS) associated with mutations…
Protein interaction may lead to new strategy for treatment of ALS
By taking advantage of a molecular interaction between the disease-related protein TDP-43 and another, innocuous protein, scientists have found a…
Collaboration aims to unravel role of DNA damage in ALS
Scientists at Broken String Biosciences and the Francis Crick Institute are teaming up to study how genomic instability, or…
AAN 2024: Troriluzole may be taken with food, data suggest
Troriluzole, a new formulation of the approved amyotrophic lateral sclerosis (ALS) treatment riluzole, can be taken with or without…
AAN 2024: Stem cell therapy for ALS slows disease in some patients
Stem cell therapy, specifically treatment with mesenchymal stem cells or MSCs, did not substantially alter disease progression among people with…
Blocking KCNJ2 protein may reduce risk of ALS after brain injury: Study
In people who experience a traumatic brain injury, or TBI — which is linked to a greater likelihood of developing…
Taking part in certain recreational activities may increase risk of ALS
Taking part in certain recreational activities, including gardening, golfing, woodworking, and hunting, may increase the risk of developing amyotrophic…
MDA 2024: Blocking protein shows promise for genetic form of ALS
Blocking a protein called PTP sigma led to better nerve survival and motor function in a mouse model of…